Technical Analysis for LYRA - Lyra Therapeutics, Inc.

Grade Last Price % Change Price Change
F 8.4 -0.47% -0.04
LYRA closed down 0.47 percent on Thursday, May 6, 2021, on 84 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 11
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical LYRA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Older End-of-Day Signals for LYRA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 15 hours ago
Possible NR7 about 15 hours ago
Rose Above Lower Bollinger Band about 16 hours ago
Up 2% about 16 hours ago
Up 1% about 16 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Sinus Headaches Sinusitis Chronic Rhinosinusitis

Is LYRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.49
52 Week Low 7.9
Average Volume 91,253
200-Day Moving Average 11.93
50-Day Moving Average 12.10
20-Day Moving Average 10.39
10-Day Moving Average 9.86
Average True Range 0.79
ADX 27.8
+DI 9.62
-DI 31.84
Chandelier Exit (Long, 3 ATRs ) 9.66
Chandelier Exit (Short, 3 ATRs ) 10.26
Upper Bollinger Band 12.11
Lower Bollinger Band 8.67
Percent B (%b) -0.08
BandWidth 33.06
MACD Line -0.81
MACD Signal Line -0.64
MACD Histogram -0.1753
Fundamentals Value
Market Cap 108.59 Million
Num Shares 12.9 Million
EPS -99999.99
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 2.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.15
Resistance 3 (R3) 9.14 8.88 9.02
Resistance 2 (R2) 8.88 8.69 8.89 8.98
Resistance 1 (R1) 8.64 8.58 8.76 8.65 8.94
Pivot Point 8.39 8.39 8.45 8.39 8.39
Support 1 (S1) 8.15 8.20 8.27 8.15 7.86
Support 2 (S2) 7.89 8.08 7.89 7.82
Support 3 (S3) 7.65 7.89 7.78
Support 4 (S4) 7.65